- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG), Microscopic Polyangiitis (MPA), ANCA-Associated Vasculitis (AAV), Vasculitis
- Interventions
- Online questionnaire
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania
- Conditions
- Giant Cell Arteritis
- Interventions
- Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis, ANCA-Associated Vasculitis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 3 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Giant Cell Arteritis (GCA)
- Interventions
- Upadacitinib, Corticosteroid (CS), Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 53
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Long Beach, California + 46 more
- Conditions
- Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
- Interventions
- Not listed
- Lead sponsor
- Peter Merkel
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Vasculitis
- Interventions
- Placebo, Belimumab 10 mg/kg, Azathioprine
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
- Other
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- CNS Vasculitis
- Interventions
- Vessel Wall MR imaging
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Interventions
- Observational
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Giant Cell Arteritis, Polymyalgia Rheumatica
- Interventions
- Secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Boca Raton, Florida • Zephyrhills, Florida • Willowbrook, Illinois + 5 more
- Conditions
- Temporal Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
- Interventions
- Obinutuzumab, Rituximab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
- Interventions
- SC291
- Biological
- Lead sponsor
- Sana Biotechnology
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
- Interventions
- triamcinolone acetonide (Triesence®)
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio